

# Drug-Resistant Cancer Therapeutics with 2-Aryl-2-(3-Indolyl) Acetohydroxamates

## Challenge


According to the World Health Organization, in 2020, cancer was the leading cause of death - corresponding to nearly 10 million or one (1) in six (6) deaths world-wide. Cancer can occur in different parts of the body - some cancers are intrinsically drug-resistant and some quickly become drug-resistant to even the front-line therapies. Novel anticancer agents are needed to overcome these intrinsic or developed tumor resistance.

## Solution

Newly developed therapeutics to overcome drug-resistant mechanisms of cancer cells and promote cancer cell differentiation into non-proliferating "normal-like" cells.

## Benefits and Features

- Novel chemotype to treat multi-drug resistant cancers
- Compounds formulated into pharmaceutical compositions
- Orally bioavailable compounds with initial testing in mammalian animal models



## Market Potential / Applications

This invention can be used to develop clinical drugs or in partnership with a pharmaceutical drug company

## Developments and Licensing Status

*Status:* Available

*Commercial sponsor sought?* Yes

## Patent Status

US Patent Issued US 9,206,124 B2

## Inventors

Alexander Aksenov; Snežna Rogelj; Liliya Frolova; Alexander Kornienko; Gabriel Avilucea

**Keywords:** cancer, pharmaceutical compounds, prodrug, cancer

To inquire about this technology call (575) 835-5390 or email us at [OIC@nmt.edu](mailto:OIC@nmt.edu)

<https://www.nmt.edu/oic/>